Two Biotech CEOs charged in securities fraud schemesBusiness, TherapeuticsThe federal indictment alleged the two executives engaged in “false and misleading representations and material omissions” regarding the development of experimental monoclonal antibody leronlimab. Read more December 21, 2022/by BioSpace https://www.pharmalive.com/wp-content/uploads/2022/12/DOJ.jpeg 478 500 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2022-12-21 23:00:372022-12-22 08:59:14Two Biotech CEOs charged in securities fraud schemes
